Bengaluru, 12th June 2025:  Iom Bioworks, a deep science company pioneering microbiome-focused healthcare has secured Seed Round funding in their  Rs 4 Cr Seed Round led by Inflection Point Ventures (IPV). The capital will be leveraged for marketing, secure intellectual property claims, strengthen core infrastructure and scale scientific and commercial teams.

Founded in 2022, Iom Bioworks personalises health by identifying key bacteria in the gut and modulating them in a targeted manner for enhanced, improved  overall health and well-being. Their patented platform combines large-scale knowledge graphed mined through Artificial Intelligence (AI)  and advanced modelling techniques that ensures Iom achieves precise and personalized recommendations for its users.

Iom Bioworks reached more than 500 customers in just the first year and have 2 patents granted and 2 in advanced stages. They have key scientific publications in leading scientific journals. Iom Bioworks have Pan India logistics and have established digital access established for personalised microbiome services.

Bipin Pradeep Kumar, Co-Founder and CEO brings strategic vision and collaborative approach to leadership, integrating microbiome research with technology, artificial intelligence and customer focus. Dr. Samik Ghosh, Co-Founder & Chief of Science & Technology, uses his expertise at the intersection of computation and biology  to develop innovative microbiome-driven health and wellness solutions that drive sustainable health for life of people and the planet. Dr. Hiroaki Kitano, Co-Founder & Chief of Research & Collaboration, a world-renowned systems biologist and AI specialist brings decades of leadership in robotics, systems biology, and AI-driven scientific discovery to create innovative collaborations.

“Lifestyle diseases have been on the rise due to multiple reasons like poor diet, stress, lack of sleep and are intimately linked to poor gut health and microbial composition. The gut microbiome plays a huge role in your digestion, immunity, metabolism, and even mood. Understanding it can help prevent a myriad of these diseases and also provide a better quality of life. Iom Bioworks is making this cutting-edge science accessible, personalised and importantly, actionable. With their vision and science, they make a compelling bet in preventive and therapeutic healthcare”, says Vinay Bansal, Founder, IPV.

“Iom Bioworks envisions a world where a healthy mind and body are achievable through informed choices that nurture the microbiome. By empowering our inner ecosystem through prebiotics and a food and lifestyle centred around the bacteria, we aim to energize daily life while preserving the joy of living. Partnering with IPV has been transformative; their supportive and diligent approach has set us firmly on the path toward this vision”, says Bipin Pradeep Kumar.

At a compound annual growth rate (CAGR) of 28%, the worldwide market for health tests, subscriptions, and wellness platforms is expected to reach USD 900 billion by 2030. Iom Bioworks is well positioned to lead this transformation to personalised accessible gut health with its scalable approach, user focus and the foundation of deep science and research.

About Iom Bioworks

Iom Bioworks is a Bengaluru-based deep science company advancing health through identifying and therapeutically modulating key bacteria to improve well-being. Combining cutting-edge biological network theory, mathematical modelling, nutritional science with the power of AI, the company provides personalized food and prebiotic recommendations.

These individualized microbiome solutions are offered to customers throughout India with at-home gut profiling kits and end-to-end digital experience. Founded in 2022, Iom Bioworks is led by a team of global experts across biology, AI, and systems health.

About Inflection Point Ventures and Physis Capital

Inflection Point Ventures (IPV) is an angel investing platform with over 23,500+ CXOs, HNIs, and Professionals to together invest in startups. The firm supports new-age entrepreneurs by providing them with monetary & experiential capital and connecting them with a diverse group of investors. IPV has launched a $50 Mn CAT 2 VC fund, Physis Capital, to invest in Pre-Series A to Series B growth-stage start-ups. The fund has already deployed capital in two startups so far, with a few deals in advanced stages of pipeline.